Save the Date - April 1-4, 2024

Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists to create a unique program to hear presentations most suited to one's personal interests by going back and forth among concurrent tracks.

With new coverage of targeting transcription factors, plus greatly expanded coverage of protein degraders, molecular glues, and artificial intelligence for early drug discovery, the 2023 event was our largest ever! For more, see our highlights video.

Next year's event will return to San Diego from April 1-4, 2024.

Speakers from industry were strongly represented in 2023, including talks from AbbVie, Amgen, Astex Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Novartis, Pfizer, and more. In addition, featured presentations were be given by the University of Washington's David Baker, Vanderbilt's Stephen Fesik, and UC Berkeley's Daniel Nomura. > View More Speakers

APRIL 10, 2023

Covalent Modifications & Induced Proximity

Targeting Transcription Factors

APRIL 11 - 12, 2023

Protein Degraders & Molecular Glues - Part 1

Fragment-Based Drug Discovery

RNA-Targeting Small Molecule Drugs

AI for Early Drug Discovery - Part 1

Small Molecule Immuno-Modulators

APRIL 12 - 13, 2023

Protein Degraders and Molecular Glues Part 2

Protein Degraders & Molecular Glues - Part 2

Protein-Protein Interactions

bRo5: Macrocyclics, Degraders & More

AI for Early Drug Discovery - Part 2

Encoded Libraries for Drug Discovery

2023 Plenary Keynotes

Targeting Nodes and Edges in Protein Networks

Michelle Arkin, PhD

Chair and Distinguished Professor, Pharmaceutical Chemistry & Director, Small Molecule Discovery Center, University of California, San Francisco

Reflections on a Career as a Medicinal Chemist in Drug Discovery

Nicholas A. Meanwell, PhD

Vice President (recently retired), Small Molecule Drug Discovery, Bristol Myers Squibb Co.

About the Event

In-person benefits of Drug Discovery Chemistry include:

Recapture the power of serendipitous face-to-face connections with colleagues and technology providers who share similar interests and challenges
Connect and schedule 1:1 meetings with the right attendees based on CHI’s matching algorithm that aligns areas of mutual interest and expertise
Join speakers live and in-person while watching others on-demand at your convenience
Take advantage of our flexible registration policy that allows you to easily transfer between in-person & virtual participation
Connect in-person with sponsors and exhibitors under responsible safety and social distancing protocols
Access in-person exhibit booths, posters, and networking roundtables
PLUS, all of the Virtual benefits as your In-Person registration includes Virtual access